Defining the role of raloxifene for the prevention of breast cancer.
Kalidas
Mamta
M
Hilsenbeck
Susan
S
Brown
Powel
P
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D015986:Confounding Factors, Epidemiologic; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D015337:Multicenter Studies as Topic; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D014481:United States / Q000453:epidemiology
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride